# Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus

> **NCT07288515** · — · RECRUITING · sponsor: **AstraZeneca** · enrollment: 50 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07288515
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-31
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07288515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07288515, "Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07288515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*